Public Private Partnerships: A Marriage of Necessity  by Rao, Mahendra
Cell Stem Cell
ForumPublic Private Partnerships:
A Marriage of NecessityMahendra Rao1,*
150 South Drive, Suite 1140, Bethesda, MD 20892, USA
*Correspondence: mahendra.rao@nih.gov
http://dx.doi.org/10.1016/j.stem.2013.01.010
Harnessing the unprecedented flexibility that iPSC technology and gene editing offer academic and industry-
based researchers requires developing an interactive model of collaboration. Such a model will have to
leverage the basic research expertise in academia with the pharmaceutical industry’s knowledge in
manufacturing and high throughput technology to be successful.Moving toward Translation
The recent discovery that any somatic cell
can be turned into a pluripotent cell or
directly reprogrammed into a different
lineage using only a small number of
well-defined inducingagents hasheralded
a new era of possibilities. The ability to
use either method to define intermediate
stages at which cells can be expanded
and purified makes it possible to obtain
sufficient numbers of differentiated cells
for a varietyofpurposes, includingscreens
(Figure 1) and autologous therapy.
Using patient-derived cells, re-
searchers can now coordinate stage-
specific differentiation into rare, difficult
to obtain, differentiated cell phenotypes,
which allows them to examine the etiopa-
thology of a particular human disease
in vitro or in vivo without the confounding
influences of immortalization, genotypic
background, and allelic variability. The
relative ease of this process and its high
degree of fidelity allows this paradigm to
be generalized so that studies can be per-
formed not just on single cell lines from
individual patients but on entire panels,
including multiple lines per patient.
It is therefore now possible to consider
obtaining cells from a series of patients
with an obscure disease, transforming
those somatic cells into induced pluripo-
tent stem cells (iPSCs), and growing
them in sufficient numbers to make this
rare phenotype widely available to indi-
vidual investigators, thus allowing them
to assess the phenotype in a multitude
of differentiated cell types. Cell sample is
no longer limiting, and sufficient cells are
available that large-scale screens that
use billions of cells are now possible.
This ability to obtain useful information
from patient-specific iPSC lines hasbeen further enhanced by our ability
to edit the human genome using gene
engineering technologies whose effi-
ciency has seen a dramatic improvement
in the last decade. Improvements in
homologous recombination technologies
and in harnessing various DNA repair
mechanisms using integrases, nucleases,
meganucleases, recombinases, and
transposases have allowed researchers
to construct reporters in safe harbor sites,
edit the genome to repair the altered site
for isogenic controls, and to consider
‘‘personalized medicine’’ as a potential
therapeutic strategy (Rao, 2011). Using
these varied tools and expertise, how-
ever, will require skill sets that are not
currently present solely in either industry
or academia and will require the formation
of new partnerships.
Why Academic Efforts Alone Are
Not Sufficient
Although the technological break-
throughs have been dramatic and have
occurred in the academic domain, several
hurdles still remain before academic
scientists will be able to transform these
technological advances into cell-based
products for translational science for
screening or therapy. Some of these
issues may seem obvious, such as simply
setting up a new process in a laboratory
and performing activity on a reasonable
scale for screening with primary cells.
Other obstacles are not as obvious. For
example, most consent forms written
in the past did not take into account
the potential use of donated cells for
screening or therapy and the recent
advances in whole-genome sequencing.
As a result, many existing lines simply
cannot be used for screening purposes.Cell Stem Cell 12Other consent agreements allowed use
of the tissue sample obtained for very
narrow or specific research purposes
and thus do not permit their usage for
making iPSC lines. These issues are rela-
tively straightforward to fix, and indeed
many efforts along those lines have
already been made (Lowenthal et al.,
2012).
Other obstacles, however, are more
subtle, and creating meaningful solutions
is not trivial. An example of one such issue
is the fact that granting mechanisms
historically developed budgets related to
supplies based on a rule of thumb of
howmuchwas spent per person in a labo-
ratory. Currently, grants are also given
over shorter time periods than in the
past with competitive renewal require-
ments over that short timeframe. These
circumstances often mean that grants
cover a period spanning 1 to 3 years
with an annual renewal process based
on progress made. However, these grant
processes and timelines are extremely
difficult for an average researcher to
adhere to while demonstrating sufficient
progress. For example, making a well-
characterized iPSC line takes about
8 months if one includes the time required
to thoroughly characterize the cells, store
sufficient numbers of cells for use and
distribution, and grow to sufficiently long
passages to obtain the requisite epige-
netic stability. Differentiating them into
appropriate phenotypes requires addi-
tional time, and with human cells, this
correlates with our own prolonged devel-
opmental stages such that the differentia-
tion into mature cell phenotypes takes
weeks and months (Ginis et al., 2004).
Two additional problems, which I call
the ‘‘big science’’ issue, compound the, February 7, 2013 ª2013 Elsevier Inc. 149
Figure 1. Partnership Opportunities in Screening
The different steps in a screening process are illustrated and the possible roles of academia, foundations,
service providers, and pharmaceutical companies are illustrated. In an ideal collaboration, academia
would develop the cells and protocols and transfer them to a service provider, who would scale up the
assay and deliver the cells to pharma, who would run the assay for discovery or other kinds of screens.
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easily make iPSCs, making a differenti-
ated cell of an appropriate phenotype
requires skills and expertise that are
different from themolecular skills required
to perform engineering, and these are in
turn different from the skills required to
perform next-generation sequencing and
handle these databases. Most laborato-
ries are not of the size and scale that
allows one to maintain the necessary
infrastructure to perform all of these
experiments, and the few large centers
that have recognized this problem (Ginis
et al., 2004; Lowenthal et al., 2012)
have used a core model that uses
different core facilities, which often are
not sufficiently coordinated to effectively
work together throughout this multistep
process. As a result, while big science is
required, academic institutions and labs
don’t have the means to do this, and
even when they do, the appropriate fund-
ing or review processes to enable such
cross-disciplinary activity is lacking.
The NIH has recognized this inability as
a problem and has made efforts to fund
such cores, but within current budget
climates such efforts are limited and still
remain distributed over multiple institu-150 Cell Stem Cell 12, February 7, 2013 ª201tions (Hazard et al., 2011). The only
other organizations that can collate all of
these efforts under one roof are founda-
tion-funded efforts or pharmaceutical-
company-lead efforts.
Why Industry Alone Has Been
Unable to Respond to the Challenge
with Pluripotent Cells
One might imagine that if academics
cannot perform big science because of
time, process, and infrastructure issues,
then perhaps such experiments are best
left to industry, and indeed one could
make a reasonable argument as to why
this has worked in the past and
should work for iPSCs and their deriva-
tives. However, upon closer examination,
several explanations arise as to why this
has not happened and why it might
actually be difficult for pharmaceutical
companies to do this alone (see Figure 1).
Many of these issues are common to
other avenues of research, and I won’t
belabor them here. Briefly, they include
the inability to share information, the lack
of incentive to publish, their own R&D
budget cuts, and quarter to quarter
productivity demands that are difficult
for an R&D organization to meet (Pienta,3 Elsevier Inc.2010). Instead, I would like to emphasize
that there are specific obstacles pre-
sented by industry-based approaches
that have more direct relevance to stem
cell research that concern issues
regarding licensing and access to tissue
and replication of existing data from labo-
ratory-scale processes and transfer of
such to a large scale.
The process of making iPSC lines
includes tissue sourcing and consent
issues that are difficult for pharmaceutical
companies to overcome, material owner-
ship interests in the cells, process
patents, and issues with patent owner-
ship regarding reagents used for iPSC
generation, such as vectors that went
into the cells and patented protocols for
obtaining specific differentiated cell types
(Bubela et al., 2012). Obtaining such
licenses is a time consuming, expensive,
and difficult task, because each group
has an exaggerated sense of their
component’s importance in the overall
process. This problem is further com-
pounded by the fact that in general one
would like to run panels of lines, each of
which may be generated by a different
group with different licensing demands.
Even if licensing demands can be met,
there are additional problems to working
with human tissue related to testing
samples, issues of privacy, and the
consent restrictions that may accompany
tissue donation (Lowenthal et al., 2012).
These restrictions are easily surmount-
able for academic hospital-based investi-
gators, but are an additional hurdle for
pharmaceutical-based investigators.
Even in cases when pharmaceutical-
based investigators may be willing to
address these consent issues, financial
concerns may dissuade them. Pharma-
ceutical companies have already devel-
oped a strong record in using primary cells
for their screens, and so developing
models based on iPSCs may not be
consideredadvantageous fromabusiness
perspective. Furthermore, in light of the
budgetary constraints and layoffs facing
the industry, the substantial resources
and determination needed to mount
game-changing efforts that would not be
realized for many years may be lacking.
Can Working Together Work,
and If So, What Would It Take?
One can imagine several solutions to such
an impasse, and indeed, several efforts
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undertaken by foundations, the NIH, and
some of the state funding initiatives is
the generation of large panels of lines
and making them available to both
academic and nonacademic entities
for use. Examples of such initiatives
include the STEMBANCC initiative
(http://blogs.nature.com/news/2012/12/
e50-million-project-aims-to-produce-1500-
stem-cell-lines-for-drug-discovery.html),
the NYSCF initiative (http://www.NYSCF.
org), and the CIRM initiative (http://www.
cirm.ca.gov). In each case, the public
entity has made an effort to resolve the
tissue sourcing issue by ensuring that
pharma will have access to the iPSC lines
and that large panels of disease-specific
lines will be available. In many of these
initiatives, the public entity has also asked
private tool and reagent providers to
provide the scale required to manufacture
and differentiate the cells.
A slightly different example is that of
a service provider, in collaboration with
academic scientists, generating the data
required for pharmaceutical companies
to adopt a primary cell screen for toxi-
cology assays. A smaller-scale example
of this approach was taken by the Parkin-
sons Disease foundation, which con-
tracted with Life Technologies to develop
key tools required by researchers and
pharma (https://www.michaeljfox.org/
foundation/researchers.php?id=1110).
In this case, the tools were developed
to screen for factors involved in the
LRRK2 pathway, which is commonly
mutated in Parkinson’s disease patients,
and further leveraged the industry exper-
tise with Life Technologies performing
the screen in patient-specific populations.
Similarly, GE has made commitments
with academic partners for the large-
scale manufacture of human cardiomyo-
cytes. More importantly, they compared
the human cardiomyocytes side by
side with cardiomyocytes from other
species (Peng et al., 2010) and showed
that this approach was worth thecost difference (http://www.nibib.nih.gov/
nibib/file/NewsandEvents/Symposiumand
Workshops/AIMBE2012/S2_NThomas_
StemCellTechForPreClinicalDrugDiscovery.
pdf). In both examples cited above,
neither GE nor Life Technologies alone
could have developed the models or
tested them, but rather, each needed to
work with academic experts and even
other service providers and foundations
to garner the necessary infrastructure
and expertise required to make a
commercially viable resource.
A third example is the model of investi-
gators working directly with pharmaceu-
tical companies in a collaboration that is
somewhat different from past partner-
ships where academia looked to pharma
as an outlet for licensing promising tech-
nologies. In a study reported in this issue
of Cell Stem Cell, Nissim Benvenisty and
colleagues have used this creative
approach. Ben-David et al. (2013) devel-
oped a high-throughput assay to screen
for compounds that were toxic to stem
cells, but not to differentiated progeny,
in an effort to increase the purity of differ-
entiation cultures (Ben-David et al., 2013).
It is important to note that these results
could not have been obtained without
such a partnership, not from a lack of
ingenuity or ideas but more simply
because it would not be possible to iden-
tify the best targets for such a screen
without access to the compounds and
their associated databases. Indeed, our
own earlier efforts for developing
a ‘‘stem cell kill’’ assay (Han et al., 2009)
in an academic setting, while showing
proof of principle, could simply not
perform the experiment as rigorously
and elegantly as Dr. Benvenisty.
In each of these examples one can
see that no single entity could have
completed the process independently of
the other. However, working together,
these separate actors could harness
complementary expertise and access to
unique resources to effectively leverage
the potential of iPSCs.Cell Stem Cell 12In Closing
Public private partnerships may be a way
to accelerate the field. Academic centers
can generate panels of lines and develop
protocols to differentiate the cells. In
parallel, service providers can provide
these differentiated cells in assay-ready
formats to pharmaceutical companies,
and these companies can focus on
running screens with their annotated
compound libraries and depth of exper-
tise in medicinal chemistry to develop
products. A key to any partnership is
understanding the legal obligations and
clarifying patent and ownership issues. I
believe that this agreement is certainly
possible and is necessary given the
present constraints.
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